NEW YORK, NY / ACCESSWIRE / October 31, 2018 / Pharmaceutical giant Pfizer was little changed on Tuesday despite mixed earnings and news about price increases on drugs from its CEO Ian Read. Shares of Daxor Corporation were exploding as the company announcing the publication of promising data.
RDI Initiates Coverage on:
Daxor Corporation shares were up nearly 87% on Tuesday on about 5.3 million shares traded. The biotech company saw its shares gain after announcing the publication of encouraging new data in the Journal of the American College of Cardiology – Heart Failure. The new study cites 82% reduction in mortality and 56% reduction in rehospitalization 30 days after therapy guided by Daxor’s BVA-100 blood volume analyzer in acute heart failure patients. "This is a landmark study for Daxor as it provides peer review validation in a leading cardiology journal of the value of our technology and its potential to improve heart failure outcomes. Heart failure represents one of the largest areas of
Access RDI’s Daxor Corporation Research Report at:
Pfizer Inc. shares were down 0.79% yesterday on roughly 33.6 million shares traded. The Company reported earnings that beat on
Access RDI’s Pfizer Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.